Clinical Trial

Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY

Study acronym: EpiTALY
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This is a prospective, observational study on approximately 70-100 Real World participants affected by LGS, DS, or TSC treated with Epidyolex® as prescribed in the summary of product characteristics. The eligible participants are expected to participate in the study for a duration of 52 weeks of treatment.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-04
notable Enrollment increased: 100 -> 111 participants 2026-06-04
Trial Details
NCT Number NCT05485831
Lead Sponsor Jazz Pharmaceuticals
Collaborators: Advice Pharma Group srl
Conditions Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
Enrollment 111 participants
Start Date 2025-02-24
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-06-03